Arietis Pharma is a Boston-based biotechnology company focused on the discovery and development of novel antimicrobial agents. Our drug discovery pipeline focuses on sterilizing antibiotics that target Staphylococcus aureus, a leading cause of nosocomial and community acquired infections, and Helicobacter pylori, a cause of gastric ulcers and cancer. Pathogenic bacteria continually develop and spread resistance, causing the efficacy of antibiotics to diminish with time. Antibiotics are indispensable for basic healthcare and enable much of modern medicine. Without them, routine surgeries and superficial infections could become life-threatening. Founded in 2006, Arietis bridges an important gap in antimicrobial drug discovery and development. Arietis has forged productive alliances and partnerships within the biotechnology community as we advance our capacity to develop effective antibacterials. Arietis is committed to building value for its partners, shareholders, and society as a whole by providing innovative solutions for the problems of antibiotic tolerance and resistant infections.